Abstract
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death and is associated with a dismal median survival of 2–9 months. The fundamental limitations and ineffectiveness of current HCC treatments have led to the development of a vast range of nanotechnologies with the goal of improving the safety and efficacy of treatment for HCC. Although remarkable success has been achieved in nanomedicine research, there are unique considerations such as molecular heterogeneity and concomitant liver dysfunction that complicate the translation of nanotheranostics in HCC. This review highlights the progress, challenges, and targeting opportunities in HCC nanomedicine based on the growing literature in recent years.
Reference334 articles.
1. Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications
2. Hepatocellular carcinoma: Current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics;Dhanasekaran;Hepatic Med. Evid. Res.,2012
3. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas
4. Aflatoxins as a cause of hepatocellular carcinoma;Kew;J. Gastrointest. Liver Dis.,2013
5. Aflatoxins, hepatocellular carcinoma and public health
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献